R Anthony Laughrey, Chief Executive Officer, Cedarburg Hauser.
GRAFTON, US: Cedarburg Hauser Pharmaceuticals (CHP) has expanded the capacity of its Wisconsin based active pharmaceutical ingredient (API) manufacturing plant. The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by additional upgrades aimed at improving safety and GMP systems.
“These improvements increase our total reactor capacity by nearly 50 per cent. We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs,” said John Flahive, newly hired Director of Operations, Cedarburg Hauser.
In addition to the new reactors, Cedarburg Hauser has also made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities and upgraded their Emerson DeltaV Digital Automation System.
“The flexibility afforded by the additional reactor capacity allows us to better meet our customer’s on-time and on-budget requirements. We will continue to invest in our business as we strive to be the premier contract API manufacturer,” commented R Anthony Laughrey, Chief Executive Officer, Cedarburg Hauser.
© WOC News